tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Spyre Therapeutics Inc

SYRE
Add to Watchlist
89.780USD
-2.190-2.38%
Market hours 09/23, 10:20（ET）
7.80BMarket Cap
LossP/E TTM

Spyre Therapeutics Inc

89.780
-2.190-2.38%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

SYRE Financials

See Spyre Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
7.80B
Dividend TTM
0.00
P/E TTM
-35.09
EPS TTM
-2.56
Revenue
0.00
Net Profit
-208.02M
ROE
-42.63%
ROA
-26.91%

Spyre Therapeutics Inc Earnings Date

Latest Release
Aug 4, 2026
EPS / Forecast
-0.43/-0.76
Revenue / Forecast
--/0.00

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
29.79%-0.43
-18.25%-0.88
18.30%-0.83
86.35%-0.19
28.99%-0.61
38.15%-0.74
74.71%-1.02
85.48%-1.36
98.49%-0.86
75.42%-1.20
18.43%-4.02
---9.34
---56.79
---4.89
---4.93
---20.17
----
----
----
----
Revenue
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
10.08%688.00K
-85.46%198.00K
-95.39%168.00K
-87.56%174.00K
-95.44%625.00K
--1.36M
--3.64M
--1.40M
Net Profit
1.41%-36.20M
-54.12%-69.00M
-11.07%-62.53M
83.80%-11.18M
5.46%-36.72M
-2.09%-44.77M
10.90%-56.30M
-72.11%-69.03M
82.11%-38.84M
-138.07%-43.86M
-235.67%-63.18M
-119.96%-40.11M
-872.45%-217.08M
24.61%-18.42M
7.94%-18.82M
10.21%-18.23M
-226.84%-22.32M
-34.13%-24.44M
9.99%-20.45M
-12.61%-20.31M
Net Margin
----
----
----
----
----
----
----
----
----
----
----
----
---31552.47%
---9304.04%
---11203.57%
---3007.54%
----
----
----
----
Gross Margin
----
----
----
----
----
----
----
----
----
----
----
----
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
----
Debt to assets ratio
----
----
----
----
----
----
----
----
----
----
-100.00%0.00%
--0.00%
--0.00%
--0.00%
--0.02%
--0.00%
----
----
----
----
Income Statement
Revenue
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
10.08%688.00K
-85.46%198.00K
-95.39%168.00K
-87.56%174.00K
-95.44%625.00K
--1.36M
--3.64M
--1.40M
Operating profit
-57.19%-81.64M
-41.21%-75.64M
6.66%-57.17M
-2.70%-56.89M
-17.64%-51.94M
-12.13%-53.57M
-28.27%-61.25M
-66.62%-55.39M
-147.91%-44.15M
-154.04%-47.77M
-149.21%-47.75M
-77.25%-33.24M
20.58%-17.81M
23.06%-18.81M
6.26%-19.16M
7.58%-18.75M
-234.42%-22.42M
-34.22%-24.44M
10.25%-20.44M
-11.97%-20.29M
Net Profit
1.41%-36.20M
-54.12%-69.00M
-11.07%-62.53M
83.80%-11.18M
5.46%-36.72M
-2.09%-44.77M
10.90%-56.30M
-72.11%-69.03M
82.11%-38.84M
-138.07%-43.86M
-235.67%-63.18M
-119.96%-40.11M
-872.45%-217.08M
24.61%-18.42M
7.94%-18.82M
10.21%-18.23M
-226.84%-22.32M
-34.13%-24.44M
9.99%-20.45M
-12.61%-20.31M
Balance Sheet
Current assets
117.69%1.17B
34.08%763.95M
27.82%777.78M
19.84%504.60M
23.66%538.83M
16.93%569.77M
78.16%608.47M
104.46%421.08M
81.64%435.74M
998.08%487.27M
448.57%341.53M
150.49%205.95M
148.21%239.89M
-38.87%44.38M
-37.04%62.26M
-30.03%82.22M
-28.07%96.65M
-52.05%72.60M
-33.98%98.89M
-18.62%117.51M
Total current liabilities
-23.79%63.30M
20.49%85.16M
8.56%58.69M
-19.58%46.27M
275.46%83.06M
65.07%70.68M
69.05%54.06M
28.23%57.54M
-90.47%22.12M
238.83%42.82M
118.19%31.98M
153.83%44.87M
1364.09%232.23M
-22.46%12.64M
-27.24%14.66M
-13.46%17.68M
-23.01%15.86M
-49.65%16.30M
22.51%20.14M
42.37%20.43M
Total assets
117.69%1.17B
34.08%763.95M
27.82%777.78M
19.83%504.60M
23.57%538.83M
16.85%569.78M
77.99%608.48M
103.16%421.09M
79.06%436.07M
829.60%487.60M
380.52%341.86M
126.36%207.26M
128.22%243.53M
-36.93%52.45M
-35.28%71.14M
-29.05%91.57M
-27.40%106.71M
-49.17%83.17M
-31.98%109.93M
-17.07%129.06M
Total liabilities
-13.48%71.86M
6.85%93.14M
-31.03%62.55M
-47.17%49.50M
34.66%83.06M
6.40%87.17M
23.73%90.68M
42.92%93.70M
-75.68%61.68M
335.76%81.93M
251.69%73.29M
173.05%65.56M
1024.50%253.57M
-12.61%18.80M
-19.80%20.84M
-11.00%24.01M
-19.34%22.55M
-46.03%21.51M
19.27%25.98M
39.38%26.98M
Total equity
141.60%1.10B
39.00%670.81M
38.13%715.24M
39.01%455.10M
21.74%455.77M
18.96%482.61M
92.80%517.80M
131.04%327.39M
3826.71%374.38M
1105.50%405.67M
433.89%268.57M
109.76%141.70M
-111.94%-10.05M
-45.42%33.65M
-40.07%50.30M
-33.82%67.56M
-29.29%84.16M
-50.18%61.66M
-39.97%83.94M
-25.09%102.08M
Cash Flow Statement
Net operating income
-50.07%-69.88M
-39.95%-57.37M
-19.84%-44.58M
-26.16%-37.12M
25.20%-46.56M
-43.63%-40.99M
-19.86%-37.20M
14.96%-29.42M
-274.02%-62.25M
-61.86%-28.54M
-71.09%-31.04M
-129.61%-34.60M
19.49%-16.64M
32.86%-17.63M
5.85%-18.14M
11.36%-15.07M
-1092.94%-20.67M
-34.48%-26.26M
-12.47%-19.27M
3.06%-17.00M
Net investment
-477.10%-297.90M
92855.74%56.58M
-45.07%-247.41M
-41.51%25.00M
165.55%79.00M
99.94%-61.00K
-383.51%-170.54M
143.78%42.74M
-1882.81%-120.52M
-691.34%-104.96M
-351.94%-35.27M
-691.74%-97.63M
801.33%6.76M
-31.09%17.75M
44.88%14.00M
185.60%16.50M
101.58%750.00K
176.98%25.76M
-66.24%9.66M
-0.12%5.78M
Net financing
59079.62%432.60M
9704.00%12.26M
38.66%312.81M
-136.33%-4.64M
103.06%731.00K
-99.93%125.00K
37.89%225.60M
201.99%12.78M
-99.83%360.00K
1721550.00%172.16M
2045175.00%163.61M
-9539.23%-12.53M
390.59%209.99M
-16.67%10.00K
-110.00%-8.00K
-111.37%-130.00K
22393.75%42.80M
-96.69%12.00K
-99.68%80.00K
343.02%1.14M

FAQs

What are the current assets of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its current assets were 777.78M, with a year-on-year change of 27.82.

What are the total assets of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its total assets of Spyre Therapeutics Inc were 777.78M, with a year-on-year change of 27.82.

What are the total liabilities of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its total liabilities of Spyre Therapeutics Inc were 62.55M, with a year-on-year change of -31.03.

What is the total equity of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its total equity of Spyre Therapeutics Inc was 715.24M, with a year-on-year change of 38.13.

What is the net operating income of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its net operating income of Spyre Therapeutics Inc was -219.56M, with a year-on-year change of -5.27.

What is the net investment of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its net investment of Spyre Therapeutics Inc was -143.47M, with a year-on-year change of 59.39.

What is the net financing of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its net financing of Spyre Therapeutics Inc was 309.02M, with a year-on-year change of -24.79.

What is the Earnings Per Share (EPS) of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -2.42, with a year-on-year change of 45.22.

What is the net income of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its net income was -155.20M, with a year-on-year change of 25.39.

What is the Return on Equity (ROE) of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -33.69, with a year-on-year change of 70.76.

What is the Return on Assets (ROA) of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -22.39, with a year-on-year change of 48.85.

What is the operating profit of Spyre Therapeutics Inc?

According to Spyre Therapeutics Inc's FY2025 earnings report, its operating profit was -219.56M, with a year-on-year change of -5.27.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy